Condition
Ataxia-Telangiectasia (A-T)
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 3 (1)
Trial Status
Active Not Recruiting1
Terminated1
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07380165UnknownPrimary
Expanded Access Program (EAP) of Levacetylleucine for Ataxia-Telangiectasia (A-T)
NCT06673056Phase 3Active Not Recruiting
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
NCT02246491Not ApplicableTerminatedPrimary
Cell-Based Approaches For Modeling and Treating Ataxia-Telangiectasia
Showing all 3 trials